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Abstract
Objective: Intravaginal exposure to simian immunodeficiency virus (SIV) acutely recruits
interferon-alpha (IFN-α) producing plasmacytoid dendritic cells (pDC) and CD4+ T-lymphocyte targets to the endocervix of nonhuman primates. We tested the impact of repeated cervicovaginal exposures to noninfectious, defective SIV particles over 72 hours on a subsequent cervicovaginal
challenge with replication competent SIV. Methods: Thirty-four female Indian Rhesus macaques were
given a 3-day twice-daily vaginal exposures to either SIVsmB7, a replication deficient derivative of
SIVsmH3 produced by a T lymphoblast CEMx174 cell clone (n = 16), or to CEM supernatant controls
(n = 18). On the fourth day, animals were either euthanized to assess cervicovaginal immune cell
infiltration or intravaginally challenged with SIVmac251. Challenged animals were tracked for
plasma viral load and CD4 counts and euthanized at 42 days after infection. Results: At the time of
challenge, macaques exposed to SIVsmB7, had higher levels of cervical CD123 pDCs (P = 0.032) and
CD4+ T cells (P = 0.036) than those exposed to CEM control. Vaginal tissues showed a significant
increase in CD4+ T-cell infiltrates (P = 0.048) and a trend toward increased CD68+ cellular infiltrates.
After challenge, 12 SIVsmB7-treated macaques showed 2.5-fold greater daily rate of CD4 decline (P
= 0.0408), and viral load rise (P = 0.0036) as compared with 12 control animals. Conclusions: Repeated
nonproductive exposure to viral particles within a short daily time frame did not protect against
infection despite pDC recruitment, resulting instead in an accelerated CD4+ T-cell loss with an increased rate of viral replication.
Keywords: simian immunodeficiency virus, nonhuman primate, CD4, plasmacytoid dendritic cells,
cervicovaginal mucosa

Introduction
Women comprise over half of all individuals living with HIV-1 worldwide with intravaginal sex as the predominant route of transmission.1 However, the rate of infection among
exposed females is statistically low, indicating that only a fraction of viral exposures result
in productive infection.2–5 At each exposure, HIV can interact with the cervical epithelium6,7
mediating cellular infiltration6,8 and potentially engaging Toll-like receptor (TLR) 7 on dendritic cells.8–10 The effects of nonproductive HIV-1 or simian immunodeficiency virus (SIV)
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cervicovaginal exposures (absent infection) on subsequent infection outcomes remain unclear.
The CAPRISA004 trial found a positive association between a preexisting inflammatory
cytokine profile within cervicovaginal fluids and subsequent HIV infection,11 supporting
previously held views that vaginal immune activation increases HIV-1 infectivity. In parallel, a study examining SIV infectivity in rhesus macaques after direct topical application
of TLR-7/9 ligands to the cervicovaginal mucosa showed increased localized inflammation
and increased viral load after challenge.12 However, there are well-documented cases of
women with a history of chronic multiyear HIV-1 exposure without infection indicating
that exposure-initiated mechanisms may reduce future infectivity on reexposure.13–15 Of
interest, studies of resistance in these women have largely failed to identify HIV-specific
responses as a determinant of protection15 but a loss of HIV-1 “resistance” in a subset of
these women after reduced sex work (i.e., HIV-1 exposure) has suggested that resistance
is sustained by innate rather than adaptive responses.16
Acute cellular changes after cervicovaginal mucosal infection have been studied. Infection is established within CD4+ T cells and other permissive cells of the lamina propria17–20
following a robust cellular infiltrate of plasmacytoid dendritic cells (pDCs) and CD4 T
cells,6 and increased mRNA expression of proinflammatory cytokines/chemokines by day
3 post infection (DPI).21 Of interest, Li et al. demonstrated that infiltrating cervical pDCs
produce interferon-alpha (IFN-α) within hours of SIV exposure, preceding CD4+ T-cell infiltrates by 72 hours.6
The anti-HIV properties of pDCs and type I IFN have been documented and involve
intrinsic and secondary antiviral mechanisms, such as the induction of tetherin or APOPBEC family members, and the modulation of innate and adaptive effectors.22–27 In a recent
clinical study in individuals with chronic HIV infection, IFN immunotherapy sustained
viral suppression during antiretroviral therapy interruption in a subset of subjects supporting the interpretation that IFN can inhibit HIV-1 production/replication.28 However,
the role of infiltrating pDCs as a source of type I IFNs and its impact on acute SIV infection
if present before infection as a result of repeated noninfectious viral exposures remains
unclear. Taking advantage of a replication-deficient SIVsmB7 clone derived from
SIVsmH3, able to bind CD4 and fuse with its target without subsequent viral replication,29–
31 we tested the hypothesis that repeated vaginal exposures to SIV in the absence of productive infection would decrease viral infection potential and/or decrease replication kinetics as a consequence of sustained cervical pDC infiltration despite the increase in local
CD4+ T-cell infiltrates.
Methods
Ethics Statement and Animal Procedures
Healthy Indian Rhesus monkeys (Macaca mulata) were acquired from the Caribbean Primate Research Center of the University of Puerto Rico (UPR)—Medical Sciences Campus
(MSC). Animals were quarantined for 6 months and maintained at the AAALAC-accredited facilities of the Animal Resources Center, UPR-MSC.
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All animal studies were approved by the UPR-MSC, Institutional Animal Care and Use
Committee (IACUC), and comply with the Guide for the Care and Use of Laboratory Animals. Animal Welfare Assurance number: A3421, Protocol number: 3380308.
In addition, steps were taken to reduce suffering in accordance with the recommendations of the Weatherall report, “The Use of Nonhuman Primates in Research.” For instance,
all procedures were conducted under anesthesia by using ketamine 10–20 mg/kg, delivered intramuscular.
Phase I: 10 (6 and 4) macaques were given either intravaginal SIVsmB7 or CEM mock
control inoculations. Inoculations were given twice daily for 3 days in either the follicular
or luteal phase, as shown in figure 1 and figure S1 (see the supplemental content following
the references). Macaques were euthanized on the fourth day.

Figure 1. Phase I/II criteria. The study was separated into 2 separate phases. Ten macaques
were used in phase I: 4 CEM mock control intravaginally inoculated animals and 6
SIVsmB7 intravaginally inoculated animals. These animals were used to assess cellular
infiltration in the cervical and vaginal epithelium. For phase II, 24 animals were divided
equally either into CEM mock control– or SIVsmB7-inoculated animals. The inoculation
sequence for phase I was repeated and SIVmac251 challenge.

Phase II: Female macaques were housed together before use in the study to allow the
animals to reach menstrual synchrony. Twenty-four macaques, 12 macaques per group,
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were given either intravaginal SIVsmB7 or CEM mock control inoculations (table 1 and fig.
1). Inoculations were given twice daily for 3 days during the luteal phase. On the fourth
day after inoculation, each macaque was given a single 1 mL challenge dose SIVmac251.
Blood was taken before the challenge and on days 7, 14, 21, and 42 to determine plasma
viral load and CD4 count. Macaques were euthanized on days42–46 based on the analysis
focused on early viral kinetics after a single exposure and infection.
Table 1. Baseline Parameters at the Time of Challenge for Phase II Animals
CEM Mock Control Treated
(12 Macaques)
Age (yrs)
Weight (kg)
Day of

challengeb

SIVsmB7 Treated
(12 Macaques)

Pa

5.0 (4–10)

4.0 (3–6)

0.0249

5.43 (3.86–11.05)

5.11 (4.26–6.24)

0.2603

41.58 (25–62)

38.50 (24–62)

0.8172

CD4 count (cells/mL)

733.0 (449.0–1085)

768.0 (602.0–1379)

0.1749

CD8 count (cells/mL)

397.5 (218.0–800)

380.0 (198.0–799.0)

0.8174

Estrogen (pg/mL)c

80.5 (37.50–149.0)

75.85 (20.0–309.0)

0.8399

4.75 (1.03–8.44)

3.855 (0.97–8.19)

0.9540

21.94 (7.603–49.19)

20.82 (7.12–55.16)

0.8399

Progesterone (ng/mL)c
Estrogen: progesterone (ratio)

Median values shown (interquartile range).
a. P values assessed using Wilcoxon rank-sum tests.
b. Calculated from time after January 1, 2011 to signify equal timing from the start of the study year.
c. Measured at day of challenge.

Euthanasia was performed only on fully anesthetized animals by injection of pentobarbital sodium at 390 mg/mL; 1 cc/10 lbs IV. Vaginal and cervical tissues were taken for analysis.
Viruses
SIVmac251 was diluted 1:2 from a 20,000 TCID50 per milliliter viral stock grown in specific
pathogen free rhesus macaque peripheral blood mononuclear cell produced by Dr. Ron
Desrosiers (New England National Primate Research Center, Harvard Medical School) and
kindly provided by Dr. Nancy Miller (NIAID) through contract #N01-AI-30018. Animals
were challenged with 1 mL of the diluted viral stock. In vivo, titration was performed as
described in the Supplemental Methods.
SIVsmB7 is a virus-like particle derived from a clone of a CEMx174 cell line stably infected with SIVsmH3. SIVsmB7 is noninfectious because of a 1.6 kbp deletion, including
integrase, vif, vpr, and vpx genes. Cell-free SIVsmB7 and CEMx174 supernatant (CEM mock
control) were isolated by standard 20% (wt/vol) sucrose gradient ultracentrifugation. P27
enzyme-linked immunosorbent assay was used to determine 500 µg P27 SIVsmB7 dose.
CEMx174 dose was established by equal protein quantification with SIVsmB7 dose.
CD4 and CD8 Counts
CD4 and CD8 counts were monitored by TruCount Absolute Count Kits (BD Bioscience,
San Jose, California) used according to manufacture protocol.
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SIV Viral Loads
Plasma viral load was assessed by quantitative reverse transcriptase-polymerase chain reaction as previously described.32 Full method can be found in the Supplemental Methods.
Immunohistochemistry
Samples from the vagina and cervix were harvested postmortem from each animal and
fixed in 4% paraformaldehyde and embedded in paraffin for sectioning, SafeFix II (Fisher
Scientific, Pittsburgh, PA), or frozen. Immunohistochemical staining for CD123, CD68,
CD4, and Mx1 was conducted as previously reported6 (For complete method, see Supplemental Methods, http://links.lww.com/QAI/A482). CD123+ cells were considered pDC as a
previous report by Li et al6 has shown that CD123+ cells infiltrating into the endocervical
subepithelium 3 days after SIV exposure stain positive for both HLA-DR and IFN-α confirming these cells are pDC.
Statistical Analysis
Cross-sectional phase 1 and phase 2 two group comparisons between SIVsmB7-exposed
and CEM mock control–inoculated animals were made using Wilcoxon rank-sum tests,
Fisher test or Student t tests. Two-tailed P values less than 0.05 were considered statistically
significant.
To evaluate the rate of change for LogVL and CD4, a change-point model with random
intercept terms for each monkey and fixed effects for baseline CD4, days-postinfection
(DPI) (overall and after 14 DPI), a group indicator for SIVsmB7 exposure, and 2-way interaction terms between DPI and group, was fitted. This model accounts for the within individual correlation in repeated measurements and allows for a different slope before and
after 14 DPI. The models are listed below, with model variables estimates described in the
results. The function (DPI–14)+ = 0 when DPI ≤ 14 and (DPI–14)+ = DPI–14 when DPI > 14.
Model Equations for SIVsmB7 or CEM-Inoculated Animals

Statistical analysis was performed using R 2.14.1 and Prism.
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Results
Phase I: Acute Cellular Infiltrates after 72 Hours of SIVsmB7/CEM Mock Control Exposure
Ten female macaques followed during their natural luteal or follicular phases were used
to initiate 3-day twice-daily SIVsmB7/CEM mock control dosing within a 3-day period after the start of a menstrual phase (as exemplified for 2 luteal-staged animals in fig. S1 in
the supplemental content). Animals were inoculated with CEM mock or SIVsmB7 as described in figure 1 and in the methods.
Consistent with previously published data showing that infectious SIV exposure resulted in acute endocervical pDC and CD4+ T-cell infiltration within 3 days of SIV exposure/infection,6 replication-deficient SIVsmB7-treated animals had a significant higher
number of endocervical CD123+ pDC (P = 0.0317, mean: 1328 cells/mm2 vs. 435 cells/mm2)
and CD4 T cells (P = 0.0357, CD4 mean: 141.2 cells/mm2 vs. 17.92 cells/mm2) as compared
with CEM mock control–inoculated animals at 72 hours (fig. 2A) irrespective of hormonal
phase. Moreover, in animals exposed to SIVsmB7, we detected a trend in increased expression of Mx1 (an IFN-stimulated gene; fig. 2A) localized in areas enriched for CD123+ cells.
This is consistent with recruitment of CD123+ pDCs to the endocervix and local production
of type I IFNs. Although exposure to SIVsmB7 did not result in increased vaginal pDC
infiltration (fig. 2B), it did result in higher levels of CD4+ cells in vaginal tissues (fig. 2B; P
= 0.0476; mean, 164.8 cells/mm2 vs. 37.95 cells/mm2). Similar to pDCs, SIVsmB7-treated animals had higher (although not statistically significant) levels of CD68 macrophages than
control animals in the cervix, but not in the vaginal tissue. Altogether, results confirm that
exposure to replication-deficient SIV can modulate the tissue microenvironment, allowing
us to directly test how these local viral-induced changes (i.e., pDC and CD4 T-cell infiltrates) would impact a challenge with infectious SIVmac251.
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Figure 2. Infiltrate staining and quantification of cervico-vaginal tissue taken from
SIVsmB7 and CEM mock control–treated animals. A, Endocervix (top panel: CD123 staining 20×·image); SIVsmB7 treatment (left) induced large-scale pDC infiltration with cells
directly underneath or near the columnar epithelium as compared with mock control (P
= 0.0317) (second panel: Mx1 staining 20× image); corresponding with increased pDC infiltration in SIVsmB7-treated macaques, there were increased levels of interferon responsive gene product (ISG) Mx1 in treated macaques compared with controls (third panel:
CD4 staining 20×·image); SIVsmB7 treatment (left) induced moderate infiltration of CD4+
T cells as compared with CEM mock treatment (P = 0.0357) (bottom panel: CD68 staining
20×·image); SIVsmB7 treatment (left) did not induce a significant increase in macrophage
infiltration as compared with CEM mock control (right), but visually, macrophages appeared closer to, and in some cases, permeated the columnar epithelium, suggesting a
trend of increased infiltration (P = 0.0952). B, Vagina (top panel: CD123 staining 20× image); SIVsmB7 treatment (left) induced no noticeable level of pDC infiltration as compared with CEM mock control–treated animals (bottom) (P = 0.2000) (middle panel: CD4
staining 20× image); SIVsmB7 treatment (left) induced a sizable increase in CD4 T-cell
staining, with many positive staining cells found directly underneath the striated vaginal
epithelium and comparably fewer cells found in the vaginal mucosa of CEM mock control–treated animals (right) (P = 0.0476) (bottom panel: CD68 staining 20× image); macaques had moderate levels of macrophage staining within the vaginal mucosa regardless
of treatment. This level of CD68 staining was not impacted by treatment (P = 0.3524). Pairwise comparisons were performed with Wilcoxon rank-sum tests.
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Phase II: Outcome of SIVmac 251 Infection after 72-Hour Preconditioning with SIVsmB7
or CEM Control
Twenty-four female macaques were challenged with SIVmac251 after undergoing 72-hour
exposure (as described above) to either SIVsmB7 (n = 12) or CEM control (n = 12). The
groups were similar in weight and inoculation date relative to menstrual cycle (table 1; see
fig. S2 in the supplemental content), and there was no significant difference in major histocompatibility complex (MHC) class I allele distribution (Fisher exact test, P > 0.05) or for
those associated with spontaneous control between groups33–35 (see table S1 in the supplemental content).
Endogenous estrogen levels at the time of challenge between SIVsmB7 and CEM mock
control arms were not significantly different (P = 0.84) (table 1), indicating the absence of
differences in estrogen-related structural epithelial factors known to impact viral infectivity.36–38
As it has been shown that cervicovaginal inflammation is common among captive rhesus macaques,39 a 28-plex nonhuman primate luminex assay was performed within 1 week
of challenge to assess levels of proinflammatory mediators in cervicovaginal lavages (CVL)
in 13 of the 24 macaques (6 SIVsmB7/7 CEM mock). Twelve of the cytokines/chemokines
tested were below the limit of detection and no cytokine/chemokine tested showed any
significant difference between groups. Results for selected cytokines and chemokines are
summarized in figure S3 (see supplemental content).
Following a single, intravaginal SIVmac251 challenge using an infectious dose previously determined through an intravaginal titration (see Supplemental Methods), all 24 macaques became infected, with a detectable viral load within 7 or 14 days postinfection (DPI)
(fig. 3B). Viral load peaked in all animals by 14–21 DPI, with a mean viral load of 6.63 and
8.02 for CEM mock control– and SIVsmB7-treated, respectively (Student t test: P = 0.0720).
Although we didn’t detect a significant difference in peak viral load, there was a trend
toward increased viral load in SIVsmB7-treated macaques as compared with CEM mock–
treated animals (fig. 3B). We did detect a statistically significant decline in CD4+ T cells at
14 DPI in SIVsmB7-treated macaques as compared with control animals (Student t test: P
= 0.0268, mean: –355.8 CD4/µl vs. CEM—120.4 CD4/µl) (fig. 3D) consistent with a more
severe CD4 depletion after infection in the SIVsmB7-treated females. Notably, 4 of the macaques in the control group (animals 8D4, M847, 31R, and 530) had lower plasma viral
loads. These animals were similar to the other animals in the control and experimental
groups in terms of MHC genotypes, batch of doses used, day of manipulation, estrogen
levels, weight, age, and history of parity (data not shown). Analysis of baseline CVL samples from 2 of these macaques, 53O and 31R, showed no difference to other infected control
macaques.
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Figure 3. Change-point model of log plasma viral load (LogVL) and CD4 for phase II macaques. A, ∆CD4 for SIVsmB7-treated macaques was significantly higher than in CEM
mock control. By 14 DPI, there was mean loss of –355.8 CD4 per microliter in SIVsmB7treated animals compared with –120.4 CD4 per microliter for controls [Student t test; P =
0.0268 (inset)]. B, Twenty-two of 24 macaques in both treatment arms reached peak viral
load on days 14 or 21. Four of the CEM macaques had significantly lower log viral loads
than the remaining 8 CEM mock macaques (t test on area under curve with P < 0.0001),
which was not explained by known correlates of spontaneous SIV control or protection
suggesting low viral load was normal variation. At no time point was difference in Log
viral load significant; however, starting at 14 DPI and ending at 42 DPI, there was a trend
toward increased viremia in SIVsmB7-inoculated macaques (Student t test; P = 0.118). C,
As we detected a significant difference in ∆CD4 between groups, we generated a linear
mixed effect spline model to investigate CD4 change between treatment groups over time
(in days, as “DPI”). This model predicts an increased loss of CD4+ T cells per day of 14.5
cells per microliter over top of the CEM mock control animals culminating at peak viremia
(day 14). D, To investigate the behavior of log viral load, a linear mixed effect spline model
for LogVL was also generated. The LogVL model predicts SIVsmB7-treated animals to
have an increased log viral load rise per day of 0.106 over top of CEM mock–treated animals up until peak viremia on day 14.
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Model of Log Viral Load Rise and CD4 Decline in Phase II Macaques
As our data detected that SIVsmB7 exposures before an infectious challenge caused a significant decline in CD4 at peak viral load after infection, we generated linear models for
CD4 or log viral load kinetics over days (DPI) and included a spline (or change-point) at
peak viral load day 14 representing the end of the acute change in variables after infection
(illustrated in both viral load and CD4 decline data in figs. 3C, D). As expected, both models showed that (1) DPI is a significant determinant of both CD4 decline and viral load rise
for animals in either group as exemplified by its coefficient β3 in control (P = 0.0436 for CD4
and P < 0.0001 for logVL; Methods and table 2) and β3′ in SIVsmB7 treated (P = 0.0408 for
CD4 and P = 0.0036 for logVL) and (2) day 14 is a valid change-point as illustrated by the
reverse of direction of estimates for β3 and β4 for the control and β3′ and β4′ for the SIVsmB7
group.
The model for CD4 T-cell kinetics closely approximated our CD4 data and indicated a
significantly different change rate between groups before day 14 (β3′, P = 0.0408; fig. 3 and
table 2). The effect of infection in the CEM mock control animals showed a loss of 10.06
CD4+ T cells per microliter each day until peak viremia (140.8 loss at peak viral load).
SIVsmB7-treated macaques had a 2.5-fold higher daily loss of CD4+ T cells totaling 25.0
CD4+ T cells per microliter per day (342.8 loss at peak viral load).
As for viral load, the model showed a significantly higher rate of change in viral load
for the SIVsmB7 over CEM control before day 14 (β3′, P = 0.0036; fig. 3 and table 2) in support of greater CD4 T-cell loss. Specifically, log viral load rise each day after infection was
predicted to be 0.553 log per day in SIVsmB7-treated macaques as compared with 0.446
log per day for CEM mock control animals. Taking into account baseline CD4 count, CD8
count, CD4/CD8 ratio, age, or weight, as independent factors did not change the model’s
output for viral load rise.
All together, our results suggest that noninfectious SIV exposures and associated conditioning of the local microenvironment result in a greater CD4+ T-cell decline with higher
viral load.
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Table 2. Intercept and Model Coefficients for CEM Control Versus SIVsmB7-Treated Macaques
from Phase II*
Coefficients for LogVL
Change-Point Models
β0

Estimate

Standard Error
1.564118

0.1373

β1

–0.13222

0.172551

0.4525

β2

–0.00176

0.001144

0.1396

0.025321

<0.0001*

β3

2.340666

P

0.446266

β4
β0′

–0.48223
–0.1968

0.034106
0.684871

<0.0001*
0.7768

β3′
β4′

0.106337
–0.1141

0.035784
0.048224

0.0036*
0.0197*

Coefficients for CD4
Change-Point Models
β0
β1

Estimate

Standard Error

323.5255
–34.6649

203.569
22.16708

P
0.1147
0.1336

β2

0.8501

0.14663

<0.0001*

β3

–10.0638

4.93237

0.0436*

β4
β0′

11.3498
–7.7609

6.64368
99.82471

0.0903
0.9388

β3′

–14.4239

6.97048

0.0408*

β4′

19.3415

9.39395

0.0418*

*Denotes significant coefficients in the model.

Discussion
We show for the first time that an early, local, innate, and CD4 T-cell response to replication-deficient SIV particles can enhance the rate of CD4+ T-cell decline and viral load rise
on a subsequent productive infection. Our results were contrary to our original hypothesis
that the observed increase in SIV-induced cervical pDC infiltrates and local IFN-mediated
mechanisms would inhibit productive infection. Instead, our data are consistent with viral
exposures acutely modulating levels of vaginal and cervical CD4+ T-cell infiltrates, providing a greater preexisting “substrate” for viral infection, potentially overwhelming any inhibition provided by pDC and resulting in an accelerated decrease of CD4+ T cells in
association with viral replication. Importantly, our data assessing the impact of recruited
pDC were collected during natural progesterone high periods independent of pharmacological treatments commonly used to synchronize animals as these have been shown to
impair pDC function.40,41
Our results parallel a report by Wang et al. where female macaques were preexposed to
TLR-9 or TLR-7 ligands, CpG, or imiquimod, respectively, before and during SIVmac251
challenge.12 Wang et al. did not quantify differences in cellular infiltrates before challenge
nor model viral kinetics to peak viral load, but did observe increased inflammatory cytokines and infiltrate after dosing and a higher viral load 8 weeks after infection. Their reported data are consistent with our observed accelerated CD4 loss and viral load rise in
SIVsmB7 pre-exposed animals. We speculate that the Wang et al. study showed a more
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marked increase in viral replication than our study due to use to 2 challenges using a
SIVmac251 one log higher (greater viral inoculum42) and use of optimized TLR-7/9 ligands, which may have induced a greater inflammatory environment (greater local immune
activation43).
Importantly, our results are directly relevant to both low-dose SIV repeated challenge
study designs commonly used in vaccine studies and to settings of repeated HIV exposures
in women. Regarding SIV study designs, our data suggest that early SIV challenges may
encounter a different microenvironment than later challenges as a result of immune cell
infiltration. Infections after repeated exposures may increase local cell targets and result in
accelerated infection kinetics and/or greater gut-associated lymphoid tissue depletion
when compared with infections occurring at the start of exposures. Per human cohorts,
our data suggest that a sex worker in an area with high HIV-1 prevalence may have different levels of intravaginal immune cell infiltration, independent of coinfections, as compared with women with low levels of HIV-1 exposure. The presence of increased CD4+ T
cells and CD68 cells in women at higher risk of HIV-1 infection or in nonhuman primates
after multiple SIV exposures may decrease the efficiency of prophylactic interventions by
increasing infection efficiency. However, it would be of interest to determine if vaccineelicited antiviral antibodies in the presence of an increase in cellular infiltration could also
provide a greater effector population to harness potentially protective antibody-depended
cell-mediated cytotoxicity mechanisms in high-risk uninfected women. Taken together,
our data suggest that SIV/HIV exposures can contribute to local immune modulation affecting the host tissue response to future viral infection as already established for other
STD coinfections.4,16,44,45 Future experiments using a lower infectious dose or repeated low
to high-dose escalation of virus would be needed to directly show if SIVsmB7 preexposures would increase infection rate over controls as suggested by our data.
Our study had limitations that we addressed. First, our replication-deficient virus,
SIVsmB7, was derived from the human cell line, CEMx174. Previous studies have shown
that xeno/allogeneic adaptive immune responses to MHC alone can block infection.46 We
found that both SIVsmB7 and CEMx174 supernatants had MHC class I and class II proteins
(see fig. S4 in the supplemental content). The 72-hours time frame used for this experiment
would limit development of adaptive xenoantigenic responses; moreover, we used a challenge virus derived from a rhesus macaque cell line to avoid this possible confounder response (Methods). It has been shown that innate allogenic responses can be rapid in
response to live tissue grafts,47 yet little is known about the speed and strength of such
responses through mucosal administration of MHC proteins. Mucosal studies to date have
only examined such responses after the induction of the adaptive response.48,49 We interpret that because MHC proteins are present in both SIVsmB7 and control, it is unlikely
there would be a differential response yet to be detected based on MHC alone. Importantly,
CD4+ T-cell and pDC infiltration was significantly greater in SIVsmB7-treated animals indicating the control proteins did not induce change in the absence of SIV proteins. As for
other proteins shown in figure S4 and table S2 (see the supplemental content), proteomic
analysis of both CEM mock and SIVsmB7 doses had comparable protein content to
SIVsmB7 outside the presence of viral proteins or Mov10. Interestingly, the presence of
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Mov10 (see table S2 in the supplemental content) in SIVsmB7 proteomic analysis is consistent with enriched particle generation, as previous reports have shown that Mov10 incorporates into viral particles.50 It has also been shown that ectopic expression of Mov10 is
an inhibitor of HIV-1/SIV infectivity50–53; however, our data together with a recent report
showing that basal levels of Mov10 had no impact on HIV-1 replication or infectivity argues against its antiviral potential.51
Second, previous studies have shown that captive rhesus macaques can have divergent
preexisting cervicovaginal inflammation.39,54 To control for this, we did random testing of
CVL from rhesus macaques and found no difference in inflammatory cytokine levels between treatment groups (see fig. S3 in the supplemental content) despite observing differential CD4 changes between groups as described. The only difference we did detect was a
1-year difference in age between groups (table 1). We do not expect this minor difference
impacts our data as previous research has evidenced no significant difference in immune
parameters, such as immune activation or serum cytokine level, among young to middleage macaques.55
Third, our conclusions address the cervicovaginal mucosa and not other mucosal routes
of exposure. Future studies will need to establish whether repeated replication-deficient
rectal exposures induce CD4+ T-cell infiltration and affect the severity of a productive infection. Intriguingly, sustained SIV-resistance has been reported following repeated lowdose intra-rectal SIV challenges, highlighting a potential difference in compartments or
difference between 72 hours versus chronic exposure effects or both.56
In conclusion, our data support a model where viral exposures in the absence of productive infection induce changes in cervicovaginal cellular infiltrates that do not prevent
infection. Furthermore, our data may indicate an added risk to repeated short-term exposures not previously identified and introduces an unaccounted tissue change variable that
may impact the outcome of SIV challenge in studies evaluating protection by low-dose
repeated challenge formats using female macaques.
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Supplemental Digital Content – Methods
SIVsmB7 and CEMx174 Proteomic Analysis
SDS-PAGE Gels
20 μl of B7 and CEM each were loaded to a 12% NuPage 1-mm-thick gel. The gel was
stained with Invitrogen Colloidal Coomassie Blue stain.
Protein Digestion
Selected bands were excised from the gel and subsequently destained using 200 μl of 200
mM ammonium bicarbonate and 50% acetonitrile for 30 min with shaking at 37°C and then
dried in a SpeedVac. This was followed by reduction/alkylation of the protein band by
adding 100 μl 20 mM TCEP in 25 mM ammonium bicarbonate at pH 8.0, incubated for 15
min at 37°C with shaking. The supernatant was discarded and 100 μl of 40 mM iodoacetamide in 25 mM ammonium bicarbonate at pH 8.0 was added and incubated for 30 min
at 37°C with shaking. The supernatant was again discarded and two subsequent washes
of 200 μl 25 mM ammonium bicarbonate were done for 15 min each with shaking. A final
wash was done under the same conditions, except 50% acetonitrile, 25 mM ammonium
bicarbonate was used for the wash. The bands were dried in the SpeedVac and were then
rehydrated with 20 μl of 0.02 μg/μl modified Trypsin (Promega) in 40 mM ammonium
bicarbonate overnight with shaking at 37°C. The next morning, the supernatant was removed to a clean tube on ice and 20 μl of 40 mM ammonium bicarbonate was added to the
gel piece for 30 min with shaking at 37°C. The supernatants were combined and 4 μl of
neat acetic acid were added to stop the digest.
Protein Identification
4 μls of the combined digest were injected onto a nanocapillary reverse-phase column (selfpacked, New Objective 75 um column terminating in a nanospray 15 um tip) directly coupled to a ThermoElectron Orbitrap mass spectrometer. A top six method was used to obtain MS and MS/MS data. A customized database was created using a Simian database
with common contaminants and bovine (tagged) added. The database was indexed for
partial tryptic searching and the resulting masses and MS/MS spectra from the Orbitrap
were searched against this database using the SEQUEST search engine [1, 2]. Subsequent
data were filtered using 5 ppm, delta cN of 0.07. Results were reported as spectral counts.
Hormone Measurements
Blood was taken every other day between days 7–23 of the menstrual cycle. Estradiol and
progesterone concentrations were measured by enzyme-amplified chemiluminescence
(Immulite 1000, Siemens). The analytical limits of sensitivity of the estradiol and progesterone assays were 15 pg/mL (references range of 20–2,000 pg/mL) and 0.1 ng/mL (reference range of 0.2-40 ng/mL), respectively.
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Immuno-histochemistry
Tissues were deparaffinized and rehydrated in deionized water. Heat-induced epitope retrieval was performed using the water-bath method (95–98°C for 10–20 min) in 10 mM
sodium citrate, pH6.0 for CD123 detection (Sc-681, 1:2000, Santa Cruz Biotechnology Inc.),
and Mx1 (1:3000, ProteinTech) and CD68 (KP1, 1:200, Dako). For CD4 detection (IF6, 1:60,
Leica Microsystems), epitope retrieval was performed using high-pressure Decloaking
Chamber (121°C for 35 sec, Biocare Medical) in 1 mM EDTA, pH 8.0, followed by cooling
to room temperature. Tissue sections were blocked with SNIPER Blocking Reagent 5%
Non-fat milk (Biocare Medical) for 1 hr at room temperature. Endogenous peroxidase was
blocked with 3% (v/v) H2O2 in methanol TBS (pH7.4) 3% [v/v] for CD68, Mx1 and CD123,
and 0.9% for CD4 detection). Primary antibodies were diluted in 10% SNIPER Blocking
Reagent in TNB blocking buffer (Tris-HCl, pH7.5, 0.15M NaCl, 0.05% Tween 20 with 0.5
Dupont blocking reagent buffer) and incubated overnight at 4°C. After the primary antibody incubation, sections were washed and then incubated with mouse, goat, or rabbit
polymer system reagents conjugated with either horseradish peroxidase or alkaline phosphatase (ENVISON kit; Dako) according to the manufacturer’s instructions, and developed with 3,3′-diaminobenzidine (Vector Laboratories). Sections were hematoxylin
counterstained, mounted in Permount (Fisher Scientific), and examined by light microscopy. Non-specific, IgG was used as isotypic control.
Whole sections of each stained slide were digitized using Scanscope (Aperio), the image
was opened in ImageScope, and endocervical areas were selected with ImageScope drawing tools for analysis. CD4+, CD68+, Mx1+ or CD123+ cells were quantified by using a positive pixel count algorithm in the Spectrum Plus analysis program (Version 9.1, Aperio).
The parameters of the algorithm were manually tuned to match the specific staining
markup image accurately over background DAB stain. Once the parameters were set, the
algorithm was applied automatically to all digital slides to measure the number of cells of
interest. Data were reported as positive staining cells per square millimeter.
DNA Isolation and MHC Genotyping
Genomic DNA was isolated from a maximum of 3.0 × 106 peripheral blood mononuclear
cells using the MagNA Pure LC system (Roche Applied Science) and the MagNA Pure LC
DNA Isolation–Large Volume protocol (version 3.0) according to manufacturer’s guidelines. The elution volume of extracted DNA was 200 μl of MagNA Pure LC DNA Isolation–
Large Volume elution buffer. DNA concentrations (ng/μl) and Abs 260 nm/Abs 280 nm
ratios were determined using a NanoDrop UV Spectrophotometer (NanoDrop Technologies). Genotyping for Mamu-A*01, A*02, A*08, A*11, B*01, B* 03, B*04, B*17, B*08, and
DRBw*201 was done as previously described [3–5].
Viral Load
Plasma samples were spiked with armored RNA (aRNA; Asurgen) and centrifuged at
25,000 x g for 1 h. Viral RNA (vRNA) was extracted from the pellet with Proteinase K (2.5
μg/μl; Life Tech) and the High Pure Viral RNA kit (Roche). Eluted vRNA (100 μl) was then
subjected to the RNA Clean and Concentrator kit (ZYMO Research) and eluted in 50 μl,
from which 15 μl were reverse transcribed using MultiScribe™ Reverse Transcriptase (Life
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Tech) in a 50-μL gene-specific reaction. Fourteen microliters of cDNA were added to TaqMan gene expression master mix (Life Tech), along with primers and a probe targeting the
gag region of SIVmac251, and subjected to 40 cycles of qPCR analyses. Fluorescence signals
were detected with an Applied Biosystems 7900HT Sequence Detector. Data were captured
and analyzed with Sequence Detector Software (Life Tech). Viral copy numbers were calculated by plotting CT values obtained from samples against a standard curve generated
with in vitro-transcribed RNA representing known viral copy numbers. The limit of detection of the assay was five copies per reaction volume or 40 copies per ml of plasma.
SIVmac251 Titration
Infectious challenge was carried out with SIVmac251. The infectious dose via intravaginal
delivery was independently determined in a titration study on 15 female rhesus macaques
upon vaginal challenge preceding our study. Macaques were intravaginally inoculated
with either a single dose of undiluted virus or a 1:5 or 1:10 dilution. All macaques given
undiluted virus became infected. Thirty-eight percent of macaques given a 1:5 dilution became infected. To achieve a dose to infect all control animals a 1:2 dilution was chosen for
the challenge dose.
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Figure S1. Phase I hormone profiles for luteal phase inoculated macaques. [Top] OA5
was inoculated with CEM mock control, and [Bottom] OCZ was inoculated with
SIVsmB7. Animal menstrual cycling was tracked for at least one month prior to inoculations to map out hormone profiles (data not shown). Dashed lines indicate start of twice
daily, a.m. and p.m., inoculations. Dashed arrows represent individual inoculations as
described in Methods. Inoculations were confirmed to take place approximately three
days after the start of the luteal phase. Animals were euthanized (solid black arrow) and
cervicovaginal tissue sections taken after the final estrogen/progesterone sample was
measured. Axis scales were altered to highlight inflection of hormone profiles from follicular to luteal phases. Estrogen (Black Line/Left Axis) Progesterone (Grey Line/Right Axis).
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Figure S2. Estrogen/progesterone profiles for Phase II macaques. Estrogen (Grey/Left
Axis) Progesterone (Dashed line/Right Axis). Horizontal dashed line indicates SIVmac251
challenge as described in Methods. Macaques were targeted for challenge during the estrogen low, progesterone high luteal phase to avoid potential reduced SIV infectivity during the follicular phase. Axes for M823, 4A1, 9F6, Av87 were modified to show change of
menstrual stage.
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Table S1. Target MHC I Genotypes for All Phase II Macaques*
Macaque ID

Study Arm

MHC I**

14R

SIVsmB7

A01/B17

3C5

SIVsmB7

A08

5D5

SIVsmB7

A01/A02

9D9

SIVsmB7

—

9F6

SIVsmB7

A01

AO76

SIVsmB7

—

AR16

SIVsmB7

A01

AV34

SIVsmB7

B01

AV87

SIVsmB7

—

AZ00

SIVsmB7

—

M830

SIVsmB7

A02

OE6

SIVsmB7

—

15S

CEM Mock Control

15S

1D1

CEM Mock Control

A08/B01

2E6

CEM Mock Control

A08

31R

CEM Mock Control

—

4A1

CEM Mock Control

A08

53O

CEM Mock Control

A08

8D4

CEM Mock Control

B01

AJ80

CEM Mock Control

A08

AP41

CEM Mock Control

A01

M823

CEM Mock Control

A01

M847

CEM Mock Control

A08

SBR113

CEM Mock Control

A08/B17

* MHC I alleles tested for include A*01, A*02, A*08, A*11, B*01, B* 03, B*04,
B*17, and B*08. A*01, B*08 and B*17 have been associated with control of
SIV infection in Rhesus macaques [33–35].
** Dashes indicate that macaque had a genotype not assessed within our
panel.
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Figure S3. Results from selected cytokines tested in CVL Cytokine Multiplex Assay.
Luminex 28-plex Assay (Invitrogen) was done according to manufacturer protocol on PBS
lavage samples obtained within 1 week prior to macaque manipulation. Nearly half of the
inflammatory cytokines tested were below the level of detection. Of those with detectable
levels of cytokine there was no significant differences between macaques, including inflammatory mediators IL-1b, IFNγ, and IL-17 and chemokines IL-8 and CCL22. P-values
were generated by two-sided Wilcoxon rank sum tests.
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Figure S4. Proteomic analysis and comparison of SIVsmB7 and CEM control. (A) Picture of pellets after ultracentrifugation. Note the similarities in size and appearance of the
pellets. (B) Silver staining of protein gels for CEM mock control and SIVsmB7 showed a
high degree of similarity outside of five distinct bands in SIVsmB7 not found in CEM
mock control. A colloidal stain was done to confirm the band differences. Once confirmed,
those bands were excised for proteomic analysis. In each of these five bands, SIV gag polyprotein or envelope was identified. (C) Top 15 proteins for SIVsmB7 and CEM mock
control organized by SIVsmB7 abundance. The list contains only 19 proteins, showing the
high degree of protein composition similarity between the two. The only truly notable
protein not found in CEM mock control is SIV gag polyprotein, which is the most abundant protein found in SIVsmB7. (D) Table showing the abundances of MHC protein fragments detected in SIVsmB7 or CEM Mock control. Individual spectral counts were
grouped according to MHC Class I or Class II for clarity.
Method: SIVsmB7 is a virus-like particle (VLP) derived from a clone of a CEMx174 cell
line infected with SIVsmH3 . Clone B7 cells have a single provirus integrated into their
20th chromosome. SIVsmB7 is noninfectious due to a 1.6 kbp deletion, including integrase, vif, vpr, and vpx genes [29]. To produce cell-free SIVsmB7 and CEM mock control,
200,000 cells/ml of Clone B7 and uninfected CEMx174 cells were cultured in RPMI 1640
(Mediatech, Inc.) supplemented with FBS. VLPs was purified on 20% (w/v) sucrose gradient by ultra-centrifugation. Figure 1B illustrates individual pellets from CEM mock control and SIVsmB7 after supernatants are removed. The pellet was resuspended in RPMI
1640 without supplementation. ELISA was done to measure P27 content. SIVsmB7 was
diluted to a concentration of 500 μg P27 SIVsmB7 per 1 ml dose. CEMx174 dose was prepared using identical techniques.

26

ABDULHAQQ ET AL., JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES 65 (2014)

Table S2. Proteomic Analysis of Individual Differential Bands from SIVsmB7 and CEM
mock control samples
CEM Band
Protein Name
Band 1
FN1 protein
Oleoyl-[acyl-carrierprotein] hydrolase
Uncharacterized protein
Dermcidin isoform 2

Coverage

Spectral
Count

14.80%

29

3.80%
2.20%

6
5

SIVsmB7 Band
Protein Name

60%

71

Filamin-A
Desmoplakin

15%
5.90%

27
17

11.90%

7

9.10%

6

44.40%

6

18.20%

3

Junction plakoglobin

4.50%

3

Desmoglein-1

Type I keratin 16; K16

8.50%

2

Ubiquitin/40S ribosomal
protein S27a

Minor Histocompatibility Antigen HA-2

Spectral
Count

Band 1
Gag Polyprotein

Hornerin

Band 2

Coverage

Band 2
23.00%

27

Gag Polyprotein

59.80%

130

34.60%

51

Alpha Actin 4

27.60%

26

Minor histocompatibility
HA-2

Kinesin-like protein
KIF23

17.20%

15

Kinesin-like protein
KIF23

28.10%

26

Intercellular adhesion
molecule 3

8.40%

7

Alpha-actinin

26.50%

26

cDNA FLJ56016, highly
similar to C-1tetrahydrofolate
synthase, cytoplasmic

8.20%

9

Major vault protein

23.60%

18

7

Putative helicase
MOV-10

16.10%

17

Ubiquitin-like modifieractivating enzyme 1

8.10%

Band 3

Band 3

Glucose-6-phosphate
isomerase

19.30%

14

Gag Polyprotein

75.70%

397

Pyruvate kinase
isozymes M1/M2

30.10%

19

Tubulin beta chain

55.20%

26

cDNA FLJ61188, highly
similar to Basigin

37.80%

13

cDNA FLJ37935 fis, clone
CTONG2005290, highly
similar to FASCIN

44.30%

23

Uncharaterized protein

31.10%

14

Coronin-1A

41.40%

18

cDNA FLJ37935 fis, clone
CTONG2005290, highly
similar to FASCIN

28.20%

14

cDNA FLJ61188, highly
similar to Basigin

37.80%

9

23.10%

13

cDNA FLJ32131 fis,
highly similar to Tubulin
alpha-ubiquitous chain

29.60%

6

Tubulin beta chain

41.20%

29

Gag Polyprotein

44.40%

41

Alpha-enolase

39.60%

28

Alpha-Enolase

41.70%

39

Coronin-1A

25.60%

16

Tubulin beta chain

45.90%

35

7.60%

5

Elongation factor 1-alpha

31.80%

26

Plastin-2
Band 4

Elongation factor 1-alpha

Band 4
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APT synthast subunit
beta, mitochondrial

15.10%

Tubulin beta-2C chain

9.40%

8

cDNA FLJ60299, highly
similar to Rab GDP dissociation inhibitor beta

43.90%

23

5

Coronin-1A

20.00%

23

Band 5
Ras-related protein
Rab-35

Band 5
15.90%

4

Gag Polyprotein

37.70%

52

cDNA FLJ75480, highly
similar to Human lactoferrin

22.50%

15

Ras-related
protein Rab-35

24.80%

8

34.70%

6

9.70%

5

RAB11B protein

19.30%

4

60S ribosomal
protein L18

13.80%

3

Uncharacterized protein

13.60%

3

Ras-related
protein Rab-11A

B-lymphocyte
antigen CD20

12.80%

3

Elongation factor 1-alpha

S-9 (Fragment)

19.00%

3

40S ribosomal protein S9

19.6%

4

Table S2. Results of individual band proteomic analysis for SIVsmB7 and CEM control. Top six
proteins from each of the excised bands shown in figure 1 from CEM mock control [Left] and
SIVsmB7 [Right]. As noted previously, SIV gag polyprotein was the dominant protein in each of
those excised bands from SIVsmB7. The remaining proteins found in those bands were comparable
to proteins identified from bands excised from CEM mock control taken from the same position in
the CEM mock control lanes. Total coverage of the given protein is shown along with total spectral
counts.
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